Market news

Detailed price information for Repligen Corp (RGEN-Q) from The Globe and Mail including charting and trades.

Repligen (RGEN) has an average rating of buy and mean price target of $189, according to analysts po

Repligen stock has delivered a strong 1 year gain, yet the broader valuation checks and recent history raise questions about how much upside is left. The intrinsic value estimate from a Discounted Cash Flow (DCF) view is close to the current share price, while market-based multiples lean more expensive. Over 5 years, Repligen shares have declined about 42%, which points to a difficult longer term journey despite a healthier recent rebound. The valuation story now hinges on whether Repligen...

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9th at 1:30 p.m. ET. A live webcast of the conference presentation will be

Detailed price information for Repligen Corp (RGEN-Q) from The Globe and Mail including charting and trades.

Repligen stock has delivered a strong 45.1% one year return, yet the valuation signals are mixed, with the Discounted Cash Flow (DCF) estimate pointing to a price that is close to intrinsic value while market based multiples suggest the shares trade at a premium. That combination leaves Repligen looking less like an obvious bargain and more like a stock where the entry price matters. Repligen’s 45.1% return over the past year highlights that recent shareholders have been rewarded. This...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Repligen (NASDAQ:RGEN) and the best and worst performers in the drug development inputs & services industry.

The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares jump after stronger-than-expected results.

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 14.6% in the afternoon session after the company reported second-quarter results that beat analyst expectations and raised its full-year forecast.

Repligen (RGEN) has an average rating of buy and mean price target of $183.67, according to analysts

Repligen's (RGEN) diversity of growth drivers and a strengthening bioprocess market should support a

Repligen (RGEN) has an average rating of Buy and mean price target of $183.67, according to analysts

Second quarter revenue of $204 million, a year-over-year increase of 12% as reported and 13% organicGAAP operating income increased 1% year-over-year while adjusted operating income increased 55%Raising both FY26 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09 WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second qu

Repligen Corp (RGEN) reports robust revenue growth and increased full-year guidance, driven by significant gains in the Proteins segment and APAC region.

Detailed price information for Repligen Corp (RGEN-Q) from The Globe and Mail including charting and trades.

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.9% year on year to $204.1 million. The company expects the full year’s revenue to be around $824 million, close to analysts’ estimates. Its non-GAAP profit of $0.54 per share was 20.4% above analysts’ consensus estimates.

Repligen (NasdaqGS:RGEN) and BioLife Solutions recently held a merger and acquisition call. The discussion focused on potential combinations or partnerships in bioprocessing and cell and gene therapy tools. The call represents new corporate activity that is separate from routine earnings updates. Repligen enters this M&A discussion with BioLife Solutions while its shares trade at $131.06. The stock is up 9.5% over the past year, although it is down 20.3% year to date and has declined 23.6%...

Repligen (RGEN) delivered earnings and revenue surprises of +20.00% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) reported Q2 adjusted earnings Tuesday of $0.54 per diluted share, up from $0.37 a ye

Repligen Corporation (NASDAQ:RGEN) reported double-digit second-quarter revenue growth and increased its full-year 2026 financial guidance, citing strong order momentum and continued market outperformance while highlighting its pending acquisition of BioLife Solutions. Key Investor TakeawaysRepligen raised its full-year 2026 guidance following stronger first-half performance and continued order momentum.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday morning. Here’s what you need to know.

Tipranks Press Release.

A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million

RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.

Repligen (NASDAQ:RGEN) said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen’s exposure to one of the faster-growing areas of bioprocessing. Presi